Trevi Therapeutics Inc. Common Stock (TRVI)
Stock · NASDAQ · Health Care
$11.88as of 10/16/2026
Price chart
Active signals
TRVI Signal Track Record
How signals performed across all stocks →What TRVI's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 43 | -1.4% | 44% | October 6, 2026 |
| Bollinger Band Breakout | 27 | +5.8% | 56% | June 16, 2026 |
| Bollinger Band Breakdown | 18 | -1.1% | 50% | September 15, 2026 |
| 200-Day Moving Average TouchActive now | 8 | -0.9% | 38% | September 30, 2026 |
| Any 20-session window (baseline) | +1.3% | 53% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About TRVI
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 34
- Website
- www.trevitherapeutics.com/
Fundamentals
- 1-day range
- $12.81$13.46
- Market cap
- $2.63B
- P/E (trailing)
- —
- P/E (forward)
- -22.41
- EPS (trailing)
- $-0.34
- Dividend yield
- —
- Beta
- 1.04
- Avg. volume
- 2.13M
Forecasts
11 analyst ratings
Trevi Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- TRVITrevi Therapeutics Inc. Common Stock$11.88▼ 1.90%Market cap $2.63BP/E —$9.28$20.22
- NRIXNurix Therapeutics Inc. Common stock$24.42▼ 2.12%Market cap $2.62BP/E 9.25$9.14$28.23
- PBHPrestige Consumer Healthcare Inc. Common Stock$49.92▲ 1.46%Market cap $2.58BP/E 13.50$42.62$71.07
- AMLXAmylyx Pharmaceuticals Inc. Common Stock$26.34▼ 4.74%Market cap $2.69BP/E —$10.83$41.14
- RAREUltragenyx Pharmaceutical Inc. Common Stock$14.54▼ 4.15%Market cap $2.54BP/E —$12.73$39.89
- SUPNSupernus Pharmaceuticals Inc. Common Stock$37.88▼ 4.27%Market cap $2.72BP/E —$39.36$59.68
- NKTRNektar Therapeutics Common Stock$35.78▼ 5.14%Market cap $2.48BP/E —$33.4$109
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TRVI Trevi Therapeutics Inc. Common Stock | $2.63B | — | $11.88 | ▼ 1.90% | $9.28$20.22 |
| NRIX Nurix Therapeutics Inc. Common stock | $2.62B | 9.25 | $24.42 | ▼ 2.12% | $9.14$28.23 |
| PBH Prestige Consumer Healthcare Inc. Common Stock | $2.58B | 13.50 | $49.92 | ▲ 1.46% | $42.62$71.07 |
| AMLX Amylyx Pharmaceuticals Inc. Common Stock | $2.69B | — | $26.34 | ▼ 4.74% | $10.83$41.14 |
| RARE Ultragenyx Pharmaceutical Inc. Common Stock | $2.54B | — | $14.54 | ▼ 4.15% | $12.73$39.89 |
| SUPN Supernus Pharmaceuticals Inc. Common Stock | $2.72B | — | $37.88 | ▼ 4.27% | $39.36$59.68 |
| NKTR Nektar Therapeutics Common Stock | $2.48B | — | $35.78 | ▼ 5.14% | $33.4$109 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Heffernan Michael Thomas · September 15, 2026 · Option Exercise21.1K @ $3.33
- Heffernan Michael Thomas · September 15, 2026 · Option Exercise18.4K @ $3.04
- Heffernan Michael Thomas · September 15, 2026 · Sale100 @ $15.88
- Heffernan Michael Thomas · September 15, 2026 · Sale21.0K @ $15.09
- Heffernan Michael Thomas · September 15, 2026 · Sale18.3K @ $15.09
- Heffernan Michael Thomas · June 3, 2026 · Grant35.0K
- David P. Meeker · June 3, 2026 · Grant35.0K
- Edward T. Mathers · June 3, 2026 · Grant35.0K
- Colangelo Dominick · June 3, 2026 · Grant35.0K
- VANLENT ANNE · June 3, 2026 · Grant35.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 134.18M
- Total value held
- $1.60B
- Institutional holders
- 194
- Unknown13.22M
- Unknown10.24M
- Unknown9.94M
- Unknown8.04M
- Unknown5.19M
- Unknown5.09M
- Unknown4.98M
- Unknown3.97M
- Unknown3.71M
- Unknown3.30M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
TRVI releases Q2 2026 earnings and makes Raymond James top health list
Trevi Therapeutics held its Q2 2026 earnings call, sharing the latest financial and operational results. In a separate note, Raymond James analysts listed the stock among their top four healthcare picks. The earnings discussion and analyst endorsement may draw additional attention to the company. The shares are trading close to the upper end of their 52‑week range.
TRVI releases Q2 2026 earnings and makes Raymond James top health list. Trevi Therapeutics held its Q2 2026 earnings call, sharing the latest financial and operational results. In a separate note, Raymond James analysts listed the stock among their top four healthcare picks. The earnings discussion and analyst endorsement may draw additional attention to the company. The shares are trading close to the upper end of their 52‑week range.